急性呼吸窘迫综合征住院死亡生物标志物与临床预测模型的外部验证
该研究在三个队列中外部验证了一个包含年龄、APACHE III、表面活性蛋白D和白细胞介素-8的ARDS住院死亡预测模型,队列包括FACTT试验849例、STRIVE试验144例和VALID观察性队列545例。模型在所有队列中表现良好,FACTT的AUC为0.74(95%CI 0.70–0.79),VALID为0.72(95%CI 0.67–0.77),FACTT与VALID合并AUC为0.73(95%CI 0.70–0.76)。虽然AUC低于原始推导队列,但模型仍表现良好,作者认为可能有助于临床试验入组的风险评估。
要点
- 验证队列包括FACTT试验849例、STRIVE试验144例和VALID观察性队列545例ARDS患者。
- 模型包含年龄、APACHE III、表面活性蛋白D和白细胞介素-8四个预测因子。
- FACTT队列AUC为0.74(95%CI 0.70–0.79),VALID队列AUC为0.72(95%CI 0.67–0.77)。
- FACTT与VALID合并后AUC为0.73(95%CI 0.70–0.76)。
- 作者认为该模型可能有助于临床试验入组的风险评估。
适用人群与场景
- 验证队列为参加临床试验或观察性队列的ARDS患者,包括FACTT试验849例、STRIVE试验144例和VALID观察性队列545例。
研究设计与关键结果
- 研究类型为预测模型外部验证,验证队列包括FACTT试验849例、STRIVE试验144例和VALID观察性队列545例ARDS患者。
- 生物标志物/临床预测模型在所有队列中表现良好,FACTT的AUC为0.74(95%CI 0.70–0.79),VALID的AUC为0.72(95%CI 0.67–0.77)。
- FACTT与VALID合并后AUC为0.73(95%CI 0.70–0.76)。
- 模型在临床试验中表现优于异质性更高的VALID观察性队列。
证据类型、等级与局限
- 证据类型为预测模型外部验证研究,验证队列来自两项临床试验和一项观察性队列研究。
- 模型性能以AUC衡量低于原始推导队列,但生物标志物/临床模型仍表现良好。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为该模型可能有助于临床试验入组的风险评估。
- 原文未据此给出急诊或ICU床旁治疗的推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Mortality prediction in ARDS is important for prognostication and risk stratification. However, no prediction models have been independently validated. A combination of two biomarkers with age and APACHE III was superior in predicting mortality in the NHLBI ARDSNet ALVEOLI trial. We validated this prediction tool in two clinical trials and an observational cohort.
METHODS: The validation cohorts included 849 patients from the NHLBI ARDSNet Fluid and Catheter Treatment Trial (FACTT), 144 patients from a clinical trial of sivelestat for ARDS (STRIVE), and 545 ARDS patients from the VALID observational cohort study. To evaluate the performance of the prediction model, the area under the receiver operating characteristic curve (AUC), model discrimination, and calibration were assessed, and recalibration methods were applied.
RESULTS: The biomarker/clinical prediction model performed well in all cohorts. Performance was better in the clinical trials with an AUC of 0.74 (95% CI 0.70-0.79) in FACTT, compared to 0.72 (95% CI 0.67-0.77) in VALID, a more heterogeneous observational cohort. The AUC was 0.73 (95% CI 0.70-0.76) when FACTT and VALID were combined.
CONCLUSION: We validated a mortality prediction model for ARDS that includes age, APACHE III, surfactant protein D, and interleukin-8 in a variety of clinical settings. Although the model performance as measured by AUC was lower than in the original model derivation cohort, the biomarker/clinical model still performed well and may be useful for risk assessment for clinical trial enrollment, an issue of increasing importance as ARDS mortality declines, and better methods are needed for selection of the most severely ill patients for inclusion.
参考来源
- Zhao Z, Wickersham N, Kangelaris KN, et al. External validation of a biomarker and clinical prediction model for hospital mortality in acute respiratory distress syndrome. Intensive Care Med. 2017. PMID: 28593401. doi:10.1007/s00134-017-4854-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。